MIR stock is viewed positively by analysts, with Citigroup recently raising its price target to $20, reflecting a 17% upside, citing strong growth drivers and favorable market trends. Baird initiated coverage with a $22 target, highlighting its robust position in nuclear and medical markets, offering a 25% potential gain. The company's share buyback plan and projected 2025 revenue growth of 4%-6% further bolster its bullish outlook.